Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant.  You'll note that several are "negative" trials -- blockbusters are hard to come by here -- but even trials that tell us what not to do are important.   And there are some hints of new approaches that could improve outcomes for patients.